FES Rowing for Skeletal Health After SCI

In this study the investigators expect to enroll a total of 10 participants with SCI. Five participants will be assigned to a Standard-of-Care (control) group and five participants will be assigned to an FES-rowing intervention group. Group assignment will be partly based on the preference of each potential participant and their willingness to make the necessary time commitment required for participation in a given group, with the added goal, to the extent possible, of matching the two groups for age, gender and time since injury. Only those individuals who have a strong desire to participate in a regular exercise program and who express a willingness to travel to VA Palo Alto the necessary number of times per week to perform FES-rowing will be potential candidates for inclusion in the rowing group.

Bone density measurements for both the Standard-of-Care group and the FES-rowing group will be performed using Dual energy X-ray Absorptiometry (DXA) and peripheral Quantitative Computed Tomography (pQCT). The Standard-of-Care group will undergo no other research procedures.

The muscle conditioning program is accomplished through electrical stimulation of the quadriceps and hamstring muscles using a 4-channel electrical stimulator that applies stimulation using surface electrodes adhered using gel to the skin overlying the quadriceps and hamstrings muscles. The muscle strengthening initially takes place three times per week, sixty minutes per session, progressing up to five sessions per week, for approximately 8 weeks. The muscle strengthening program ensures that subjects have sufficient muscle strength and endurance before they embark on the rowing program. Following the 8-week muscle strengthening program, subjects will begin FES-rowing, with three sessions per week, thirty minutes per session for the following 28 weeks. In the FES-rowing group, the investigators will measure isometric knee extension strength at the start of week 0, and at the end of weeks 12, 24 and 36.

For the rowing group, the investigators will capture 3D kinetics and kinematics in the motion capture laboratory during FES-rowing at the end of weeks 12, 24 and 36. Kinematics during rowing will be collected from fifty passive retro-reflective markers that will be placed on each participant to capture the position and orientation of the 12 interconnected body segments used to represent each subject.

Inclusion criteria

Subjects in the rowing groups:

• male and female SCI outpatients or inpatients
• have a C7 to T12, ASIA-A or ASIA-B, spinal cord injury
• be at least 18 years old
• have their physician's clearance to exercise
• between 3 and 24 months post spinal cord injury*
• minimum passive hip flexion range of motion (ROM) from 20 to 100 deg
• minimum passive knee flexion ROM from 20 to 100 deg
• minimum passive ankle ROM from +10 deg (dorsi-flexion) to -15 deg (plantar-flexion)
• currently use a manual wheelchair
• be able to perform independent and safe transfers to and from their wheelchair *There is no time post injury restriction for subjects in the experience rower group

Subjects in the control group:

• male and female SCI outpatients or inpatients
• have a C5 to T12, ASIA-A or ASIA-B, spinal cord injury
• be at least 18 years old
• between 3 and 24 months post spinal cord injury
• be able to perform safe transfers to and from their wheelchair, either independently or with assistance

Exclusion criteria

• pregnant women
• women of childbearing potential not practicing a reliable method of contraception
• women who are post-menopausal
• have mechanical instability of the spine
• resting blood pressure higher than 140/90
• a grade 1 or greater, sacral, gluteal or ischial pressure ulcer
• history of low trauma, lower limb fracture since SCI
• renal disease
• current osteomyelitis
• current thrombosis/hemorrhage
• cancer
• other neurological disease (i.e. stroke, peripheral neuropathy, myopathy)
• any implanted electronic device
• active treatment for epilepsy
• regular use of tobacco
• known coronary artery disease
• family history of sudden cardiac death
• current use of cardioactive medications, e.g., for treatment of congestive heart failure or arrhythmia
• current use of medications that can affect bone density and fracture risk including:

• bisphosphonates
• parathyroid hormone (PTH) and PTH analogs
• androgenic steroids